Kazia Therapeutics Limited

NASDAQ (USD): Kazia Therapeutics Limited (KZIA)

Last Price

0.527

Today's Change

+0.195 (58.73%)

Day's Change

0.365 - 0.56

Trading Volume

16,539,747

Overview

Market Cap

15 Million

Shares Outstanding

29 Million

Avg Volume

1,250,875

Avg Price (50 Days)

0.38

Avg Price (200 Days)

0.34

PE Ratio

-1.39

EPS

-0.38

Earnings Announcement

19-Feb-2025

Previous Close

0.33

Open

0.37

Day's Range

0.365 - 0.5598

Year Range

0.19 - 1.58

Trading Volume

16,743,358

Price Change Highlight

1 Day Change

58.70%

5 Day Change

31.73%

1 Month Change

54.97%

3 Month Change

-11.18%

6 Month Change

52.20%

Ytd Change

17.09%

1 Year Change

-16.39%

3 Year Change

-94.97%

5 Year Change

-83.27%

10 Year Change

-95.23%

Max Change

-99.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment